Beijing Innocare Pharma Tech Co., Ltd.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases (US 10,336,755) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for Heterocyclic compound as TRK inhibitor (US 11,878,987) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Crystalline Forms of 6-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)NICOTINAMIDE (US 11,945,792) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,336,755 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,710,981 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,059,805 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,572,353 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,878,987 | Heterocyclic compound as TRK inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,578,058 | Heterocyclic Compounds for Inhibiting TYK2 Activities In force · High confidence | In force | High confidence | |
| US 11,945,792 | Crystalline Forms of 6-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)NICOTINAMIDE In force · High confidence | In force | High confidence | |
| US 12,178,808 | Amorphous Solid Dispersion Comprising 6-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)NICOTINAMIDE In force · High confidence | In force | High confidence | |
| US 12,202,813 | Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide In force · From the USPTO record | In force | From the USPTO record | |
| US 12,391,666 | Indoline-1-formamide compound, preparation method therefor, and medical use thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 2 patents in force now held by others · 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 2 abandoned · 3 no status recorded